Checkpoint Therapeutics, Inc.
CKPT · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.01 | -0.09 | 0.06 |
| FCF Yield | -483.52% | -5.65% | -11.60% | -8.33% |
| EV / EBITDA | 2.75 | -4.17 | -9.46 | -10.48 |
| Quality | ||||
| ROIC | -68.42% | 228.35% | 77.24% | 42.37% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -10,826.83% |
| Cash Conversion Ratio | 1.04 | 0.25 | 1.15 | 0.94 |
| Growth | ||||
| Revenue 3-Year CAGR | -38.35% | -40.23% | -29.48% | -12.14% |
| Free Cash Flow Growth | -62.83% | 35.98% | -79.65% | 3.61% |
| Safety | ||||
| Net Debt / EBITDA | 2.96 | 0.23 | 0.48 | 0.74 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -32.61 | -111.56 | -127.81 |